Cancer

Blood Test Identifies Lung Cancer Patients Who Will Respond to Immunotherapy

Researchers at Mass General Brigham have developed a blood test that predicts tarlatamab response in small cell lung cancer, showing 85% sensitivity and 100% specificity.

Cancer

InterVenn Partners with Aranscia to Expand Ovarian Cancer Test Access

Multi-year agreement will provide clinical workflow software and laboratory support for GlycoKnow liquid biopsy test.

Cancer

Genomic Test Shows Promise for Identifying High-Risk Prostate Cancer in African American Men

A genomic test widely used in prostate cancer care can more accurately identify which men with early-stage disease face high risk of recurrence after treatment.

Cell-Free DNA Test May Identify Immunotherapy Adverse Events Earlier

Dec 12, 2025 | Cancer

Johns Hopkins researchers found the blood test detected multiorgan tissue damage in patients experiencing immune-related adverse events from checkpoint inhibitor therapy.

Ultrasensitive ctDNA Test Shows Promise for Lung Cancer Monitoring

Dec 11, 2025 | Lung Cancer

A study of 431 patients demonstrates the test can detect cancer recurrence months ahead of standard imaging.

Study Identifies Factors That Interfere with Cancer Detection in Liquid Biopsy

Dec 9, 2025 | Cancer

Research analyzing cell-free DNA fragmentation patterns in healthy individuals reveals physiological confounders that could improve test accuracy.

Natera Acquires Foresight Diagnostics in $450 Million Deal

Dec 8, 2025 | Lymphoma

Transaction expands Natera’s solid tumor MRD capabilities and adds ultrasensitive phased variant technology with detection below 0.1 parts per million.

New Partnership Aims to Expand Access to AI-Driven Cancer Genomic Testing

Dec 5, 2025 | Analytical Software Systems, Cancer, Molecular Diagnostics

The collaboration combines AI-based analysis tools with a next-generation sequencing system to support labs performing tumor and liquid biopsy testing.

ACS Updates Cervical Cancer Screening Guidelines, Adds HPV Self-Collection Option

Dec 4, 2025 | Cervical (HPV)

The new guidelines allow self-collected vaginal samples for HPV testing and outline criteria for safely discontinuing cervical cancer screening.

FDA Approves Blood-Based Prostate Cancer Test

Dec 3, 2025 | Prostate

The test receives premarket approval as an aid in biopsy decision-making for men 50 and older with elevated PSA levels.

Blood Test May Match CT for Early Lung Cancer Detection

Nov 25, 2025 | Lung Cancer

The Mercy Halo test demonstrates performance similar to low-dose CT screening with the potential to reach underscreened populations.

New Somatic Cancer Reference Standards Launched to Monitor Diagnostic Assay Accuracy

Nov 24, 2025 | Cancer

The standards developed through a public-private partnership contain seven oncogenic mutations selected for clinical significance.

Medicare Covers Ultrasensitive MRD Test for Breast Cancer Surveillance

Nov 24, 2025 | Breast

Coverage applies to stage II and III breast cancer patients across three major subtypes for up to six years of recurrence monitoring.

New Data Shows How Plasma Detect Assay May Support Cancer Treatment Decisions

Nov 21, 2025 | Cancer

Research demonstrates the MRD assay’s utility in tracking disease progression and predicting treatment outcomes.

Cancer Check Labs Expands Multi-Cancer Detection Test to New York

Nov 21, 2025 | Cancer

The blood-based screening test can detect more than 200 types of solid tumor cancers and is now available in all 48 continental states.

Plus Therapeutics Secures Humana Coverage for CNS Cancer Assay

Nov 20, 2025 | Cancer

The agreement extends CNSide cerebrospinal fluid test coverage to 16 million additional patients nationwide.

MyOme Launches Integrated Polygenic Risk Score for Prostate Cancer

Nov 20, 2025 | Prostate

The whole-genome test combines data from 7 million genetic markers with clinical risk factors to provide individualized 10-year and lifetime risk assessments.

Lunit, Labcorp Partner on AI-Powered Digital Pathology Research

Nov 17, 2025 | Analytical Software Systems, Cancer, Digital Pathology

The collaboration combines Labcorp’s clinical expertise with Lunit’s AI algorithms to analyze tumor microenvironments and enhance biomarker discovery.

Category: Cancer

Cancer

Cancer

Cancer